/PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the...

WALTHAM, Mass. & SAN DIEGO, February 14, 2025--Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commi...

First-in-class monoclonal antibody offering monthly subcutaneous treatment for HAE patients. Expands global reach following EU and UK approvals.

-94% of patients remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing its durable...

CSL Vifor announced that FILSPARI® (sparsentan) has received recommendation from England's National Institute for Health and Care Excellence (NICE) for treating IgA nephropathy. The treatment is approved for adults with urine protein excretion ≥1.0 g/day or urine protein-to-creatinine ratio ≥0.75 g/g. This marks the first non-immunosuppressive dual-action therapy recommended for this condition, which affects over 22,000 adults in England. The recommendation follows MHRA authorization in April 2025, with commercial availability expected from July 2025. IgA nephropathy, the most common primary glomerular disease worldwide, leads to kidney failure in 30-40% of patients within 10 years of diagnosis if not properly controlled. The NICE decision requires NHS England to fund the treatment within 90 days of final publication, expected on June 27, 2025.

GALLEN, Switzerland and SAN DIEGO, April 29, 2025/ PRNewswire/-- CSL Vifor and Travere Therapeutics, Inc., are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval into a standard marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein...

CSL's KOSTAIVE, outperforming traditional mRNA vaccines with 12-month antibody persistence, receives EU-wide authorization for adults 18+

European Commission authorizes groundbreaking sa-mRNA COVID vaccine showing superior antibody response and year-long protection versus traditional mRNA vaccines.